Arimidex (anastrozole), an oral aromatase inhibitor (AI), is an endocrine (hormonal) therapy for the treatment of hormone-sensitive breast cancer

in postmenopausal women. Arimidex was first launched in 1995 for the treatment of advanced disease and the first approvals for early breast cancer treatment followed in 2002. Based on the Completed Treatment Analysis of the ATAC trial - the largest breast cancer treatment study ever to report mature data - 'Arimidex' remains the only AI to confirm its superiority to tamoxifen, in both efficacy and tolerability, when used over the full recommended five-year adjuvant (postsurgery) treatment period. Arimidex has accumulated over two million patient years clinical experience and has now become the worlds most used AI, leading to it being increasingly recognised as the new standard of care for the hormonal treatment of early breast cancer. Arimidex is widely available with worldwide approval in the advanced breast cancer setting, and adjuvant early breast cancer approvals in over 80 markets worldwide. Casodex (bicalutamide) is an oral non-steroidal anti-androgen for prostate cancer. It is the world's leading anti-androgen and is available in all major European markets, the USA and Japan. Casodex was first launched in 1995 as a combination treatment (with surgical or medical castration) for advanced prostate cancer and subsequently launched as monotherapy for the treatment of earlier stages of the disease. Casodex has received approval as a monotherapy treatment in over 60 markets to date. Faslodex (fulvestrant) is a new type of targeted treatment for breast cancer. It is an Estrogen Receptor Antagonist with no agonist effects. In clinical trials, 'Faslodex' was shown to be at least as effective as the 3rd generation aromatase inhibitor, 'Arimidex', in patients with advanced breast cancer who had progressed on antioestrogen therapy. 'Faslodex' is administered as a once monthly injection. 'Faslodex' is approved in a large number of countries: IRESSA (gefitinib) was the first in a new class of anti-cancer drugs, known as epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors, to gain market approval and is currently licensed for the treatment of advanced non-small-cell lung cancer (NSCLC) in 36 countries worldwide. Approvals were based on two phase II trials, IDEAL 1 and 2, which showed IRESSA to be an effective treatment for many patients with previously-treated advanced NSCLC. Approximately 50% of patients in the IDEAL trials achieved tumour shrinkage or stabilisation of their tumour

Nolvadex (tamoxifen citrate) is an oral anti-oestrogen for breast cancer, and the world's largest selling breast cancer treatment. Nolvadex has more than 10 million patient years of use in the treatment of early and advanced breast cancer in pre- and post-menopausal women. Additionally, in 1998, the US Food and Drug Administration (FDA) approved Nolvadex (tamoxifen citrate) for the reduction of the incidence of breast cancer in women at high risk of developing the disease. Nolvadex is the first drug to be approved in the USA in this indication. The FDA also approved a further new indication for Nolvadex for the reduction of contralateral (in the opposite breast) breast cancer. Trials for paediatric use of Nolvadex are ongoing. Tomudex (raltitrexed) is an injectable cytotoxic agent for advanced colorectal cancer. Zoladex (goserelin acetate) is an injectable luteinising hormone-releasing hormone analogue (LHRHa) administered as ZOLADEX SafeSystem. It stops the production of sex hormones (testosterone and oestrogen) and is used to treat hormone-sensitive cancers of the prostate and breast (in pre-/perimenopausal women) and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, Zoladex is used in assisted reproduction.